- is caused by the presence of antibodies to the ACh receptor.
- is characterized by skeletal muscle weakness and fatigability resulting from a reduced number of ACh receptors on the muscle end plate.
- The size of the EPP is reduced; therefore, it is more difficult to depolarize the muscle membrane to threshold to produce action potentials.
- Treatment with AChE inhibitors prolongs the action of ACh at the muscle end plate and partially compensates for the reduced number of receptors.
Was this article helpful?